Dawn M. Curry is a partner in the firm’s Litigation Department and a member of the Product Liability and Government Investigations and White Collar Defense practice groups, as well as a member of the firm's Hiring Committee. Dawn's practice focuses on representing pharmaceutical and medical device companies. She also represents companies and individuals in various industries including financial and insurance services and automobile dealerships.
Dawn recently moderated a panel at ACI’s Fraud and Abuse in the Sale and Marketing of Drugs conference on the topic of Steering Clear Of Individual Accountability: What Does Reinvigorated Enforcement Mean For Responsible Corporate Officers And Counsel?
Dawn is also the chair of the firm’s Data Management and Discovery practice group. She has experience managing large-scale document collections, reviews and productions, and advising clients on drafting and implementing comprehensive document retention policies. Dawn regularly speaks as a panelist on these issues. Most recently she presented to the Massachusetts Biotechnology Council on the topic of Document Retention and e-Discovery for Life Sciences Companies. Within the last year, she was also a panelist at ARMA/Simmons College/Sedona Conference’s E-Discovery Overview program; a panelist at Massachusetts Banking Association’s Record Retention Workshop; and host of a CBI webinar on the topic of Electronic Record Retention: Legal Imperatives for Biotech, Pharmaceutical & Medical Device Companies.
Dawn co-authored They are Coming For You: Corporate Executives in the Expanding World of Financial Crime published by Aspatore Books. She co-authored an article in DRI For The Defense regarding managing physician-company conflict of interest. She also co-authored an article in the Boston Business Journal offering ten recommendations to safeguard directors from potential liability, and an article published in The Federal Lawyer regarding drug quantity ratios.
Dawn has been appointed as First Circuit Correspondent for the ABA Business Torts Committee for 2011-2012.